Physicians' Academy for Cardiovascular Education

Dual PPAR agonists in CV risk & diabetes

3' education - Dec. 11, 2012

Brief-CME

View dr Michael Lincoff, Cleveland Clinic, OH,  discuss the potential for dual PPAR agonists in targeting excess cardiovascular risk in patients with diabetes and provide an outline of the aleglitazar clinical development program at a recent VBWG meeting prior to AHA in Los Angeles.

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: